<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04600921</url>
  </required_header>
  <id_info>
    <org_study_id>DvL-2020-01</org_study_id>
    <nct_id>NCT04600921</nct_id>
  </id_info>
  <brief_title>Ertugliflozin to Reduce Arrhythmic Burden in ICD/CRT patientS (ERASe-Trial) - a Phase III Study</brief_title>
  <acronym>ERASE</acronym>
  <official_title>Ertugliflozin to Reduce Arrhythmic Burden in Implantable Cardioverter-defibrillators (ICD)/Cardiac Resynchronisation Therapy(CRT) patientS (ERASe-Trial) - a Phase III Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Klinikum Klagenfurt am Wörthersee</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Elisabethinen Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Klinik Ottakring</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University Innsbruck</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>General Hospital Linz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Klinikum Wiener Neustadt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The recent study is planned to investigate the impact of Ertugliflozin on total burden of&#xD;
      ventricular arrhythmias. Further objectives will be number of therapeutic interventions of&#xD;
      implanted devices, atrial fibrillation, heart failure biomarker and changes in physical&#xD;
      function quality of life, stress and anxiety.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind (patients and physicians), placebo controlled multi-center&#xD;
      study to evaluate the effect of ertugliflozin 5mg once daily (p.o.) for 52 weeks on the&#xD;
      ventricular arrhythmic burden and markers of physical and mental well-being as well as&#xD;
      biomarker for Heart Failure with reduced Ejection Fraction (HFrEF) and heart failure with&#xD;
      mid-range ejection fraction (HFmrEF) patients with ICD±CRT therapy. The study will be&#xD;
      conducted in 8 experienced sites in Austria with an aim to enrol 402 patients to evaluate the&#xD;
      overall study hypothesis.&#xD;
&#xD;
      Therefore, three study visits will be carried out (baseline, 1-year follow-up visit and a&#xD;
      telephone visit 4 weeks after visit 2). As part of the two on-site study visits,&#xD;
      study-specific measures, a blood sample and an echocardiographic examination will be&#xD;
      performed. The trial is completed by a telephone visit 4 weeks after the second on-site visit&#xD;
      (week 52).&#xD;
&#xD;
      It is anticipated that the study will run for 30 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 24, 2021</start_date>
  <completion_date type="Anticipated">January 6, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in number of supraventricular tachycardia (svT)/ ventricular fibrillation (VF) episodes</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of nonsustained ventricular tachycardia (nsVT) episodes</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of appropriate therapeutic ICD therapies</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in nt-proBNP levels</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of HbA1c</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospital re-admissions due to heart failure</measure>
    <time_frame>56 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospital stay</measure>
    <time_frame>56 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular Mortality</measure>
    <time_frame>56 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">402</enrollment>
  <condition>Heart Failure With Reduced Ejection Fraction</condition>
  <condition>Heart Failure With Mid Range Ejection Fraction</condition>
  <condition>Implantable Cardioverter-Defibrillators</condition>
  <condition>Cardiac Resynchronization Therapy</condition>
  <arm_group>
    <arm_group_label>Ertugliflozin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The subject will receive Ertugliflozin 5mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The subject will receive Placebo 5mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ertugliflozin 5 mg</intervention_name>
    <description>The subject will receive Ertugliflozin 5mg orally once daily for 52 weeks.</description>
    <arm_group_label>Ertugliflozin</arm_group_label>
    <other_name>Steglatro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 5mg</intervention_name>
    <description>The subject will receive Placebo 5mg orally daily for 52 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar pills</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. HFrEF or HFmrEF, and ICD±CRT therapy &gt; 3 months&#xD;
&#xD;
          2. at least 10 documented VT episodes (either nsVT or sVT ± ICD treatment) within the&#xD;
             last 12 months plus:&#xD;
&#xD;
               -  nt-proBNP &gt; 500pg/mL or&#xD;
&#xD;
               -  Left-ventricular Ejection Fraction (LV-EF) &lt; 35% or&#xD;
&#xD;
               -  hospitalization for heart failure within the last 12 months or&#xD;
&#xD;
               -  &gt; 100 nsVTs within the last 12 months&#xD;
&#xD;
               -  &gt; 1 sVT/VF within the last 12 months&#xD;
&#xD;
          3. Informed consent has to be given in written form.&#xD;
&#xD;
          4. estimated glomerular filtration rate (eGFR) &gt; 30 ml/min/1.73m2&#xD;
&#xD;
          5. Blood pressure before first drug dosing: blood pressure systolic &gt; 100 mmHg&#xD;
&#xD;
          6. Blood pressure before first drug dosing: blood pressure diastolic &gt; 60 mmHg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any other form of diabetes mellitus than type 2 diabetes mellitus, history of diabetic&#xD;
             ketoacidosis&#xD;
&#xD;
          2. Ongoing ventricular arrhythmia&#xD;
&#xD;
          3. Known allergy to SGLT-2 inhibitors&#xD;
&#xD;
          4. Haemodynamic instability as defined by intravenous administration of catecholamine,&#xD;
             calciumsensitizers or phosphodiesterase inhibitors&#xD;
&#xD;
          5. &gt;1 episode of severe hypoglycemia within the last 6 months under treatment with&#xD;
             insulin or sulfonylurea&#xD;
&#xD;
          6. Planned catheter ablation for ventricular arrhythmia&#xD;
&#xD;
          7. Planned explantation of ICD, or planned up/downgrade to/from CRT-D device&#xD;
&#xD;
          8. Existing therapy with SGLT-2 inhibitors&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dirk von Lewinski, Assoc-Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dirk von Lewinski, Assoc-Prof.</last_name>
    <phone>+43 316 385</phone>
    <phone_ext>80684</phone_ext>
    <email>dirk.von_lewinski@medunigraz.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Norbert Tripolt, PhD</last_name>
    <phone>+43 316 385</phone>
    <phone_ext>78038</phone_ext>
    <email>norbert.tripolt@medunigraz.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Klinikum Klagenfurt am Wörthersee</name>
      <address>
        <city>Klagenfurt</city>
        <state>Kärnten</state>
        <zip>9020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hannes Alber, PD MD</last_name>
      <phone>+43 463 538</phone>
      <phone_ext>31203</phone_ext>
      <email>hannes.alber@kabeg.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kepler Universitätsklinikum Linz</name>
      <address>
        <city>Linz</city>
        <state>Oberösterreich</state>
        <zip>4021</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clemens Steinwender, Univ.-Prof.</last_name>
      <phone>+43 7680 83</phone>
      <phone_ext>6220</phone_ext>
      <email>clemens.steinwender@kepleruniklinikum.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <zip>8010</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Scherr, Assoc.-Prof.</last_name>
      <phone>+43 316 385</phone>
      <phone_ext>12544</phone_ext>
      <email>daniel.scherr@medunigraz.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>620</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Stühlinger, PD MD</last_name>
      <phone>+43 50 504</phone>
      <phone_ext>22767</phone_ext>
      <email>markus.stuehlinger@tirol-kliniken.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ordensklinikum Linz Elisabethinen</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Martinek, PD MD</last_name>
      <phone>+43 732 7676</phone>
      <phone_ext>4900</phone_ext>
      <email>martin.martinek@ordensklinikum.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Wien, AKH Wien</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne Gwechenberger, MD</last_name>
      <email>marianne.gwechenberger@meduniwien.ac.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wilhelminenspital</name>
      <address>
        <city>Vienna</city>
        <zip>1160</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Nürnberg, MD</last_name>
      <phone>+43 1 49150</phone>
      <phone_ext>71003</phone_ext>
      <email>michael.nürnberg@wienkav.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Landesklinikum Wiener Neustadt</name>
      <address>
        <city>Wiener Neustadt</city>
        <zip>2700</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franz Xaver Roitinger, MD</last_name>
      <email>franz.roithinger@wienerneustadt.lknoe.at</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 19, 2020</study_first_submitted>
  <study_first_submitted_qc>October 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2020</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ertugliflozin</keyword>
  <keyword>Sodium dependent glucose transporter-2 inhibitor (SGLT-2)</keyword>
  <keyword>Heart failure</keyword>
  <keyword>ICD</keyword>
  <keyword>CRT</keyword>
  <keyword>ventricular tachycardia (VT)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ertugliflozin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

